

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

**ZJ**

**中基長壽科學**

ZHONG JI LONGEVITY SCIENCE

**Zhong Ji Longevity Science Group Limited**

**中基長壽科學集團有限公司**

*(Incorporated in Bermuda with limited liability)*

**(Stock Code: 767)**

**CHANGE OF DIRECTOR  
AND MEMBERS OF BOARD COMMITTEES**

The Board announces:

**CHANGE OF EXECUTIVE DIRECTOR AND THE CHIEF EXECUTIVE OFFICER**

Mr. Li Jiuhua has resigned as an executive director and the chief executive officer of the Company due to personal and other business affairs; Mr. Li Jiuhua has been re-appointed as an advisor to the risk management committee of the Board; and Mr. Yan Yifan has been appointed as an executive director and the chief executive officer of the Company with effect from 8 April 2022.

**CHANGE OF INDEPENDENT NON-EXECUTIVE DIRECTORS**

Ms. Wang Weixia and Mr. Chai Nan have resigned as independent non-executive directors of the Company due to personal and other business affairs with effect from 7 April 2022; and Mr. Wang Ning and Professor Huang Cibo have been appointed as independent non-executive directors of the Company with effect from 8 April 2022.

**CHANGE OF MEMBERS OF BOARD COMMITTEES**

- (i) Ms. Wang Weixia ceased to be the chairman of the remuneration committee and a member of each of the audit committee, the nomination committee, the risk management committee and the share award committee of the Board with effect from 7 April 2022;

- (ii) Mr. Chai Nan ceased to be a member of each of the audit committee, the remuneration committee, the nomination committee, the risk management committee and the share award committee of the Board with effect from 7 April 2022;
- (iii) Mr. Wang Ning has been appointed as the chairman of the remuneration committee and a member of each of the audit committee, the nomination committee, the risk management committee and the share award committee of the Board with effect from 8 April 2022;
- (iv) Professor Huang Cibo has been appointed as a member of each of the audit committee, the remuneration committee, the nomination committee, the risk management committee and the share award committee of the Board with effect from 8 April 2022; and
- (v) Mr. Yan Li has been appointed to replaced Mr. Lee See Barry as the chairman of the risk management committee of the Board with effect from 8 April 2022.

#### **RESIGNATION OF EXECUTIVE DIRECTOR AND CHIEF EXECUTIVE OFFICER**

The board (the “**Board**”) of directors (the “**Director(s)**”) of Zhong Ji Longevity Science Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) hereby announces that Mr. Li Jiuhua (“**Mr. Li**”) has resigned as an executive Director and the chief executive officer of the Company due to personal and other business affairs and has been re-appointed as an advisor to the risk management committee of the Board with effect from 8 April 2022. Mr. Li has confirmed to the Board that he has no disagreement with the Board and there is no matter relating to his resignation that needs to be brought to the attention of the shareholders of the Company. The Board would like to take this opportunity to express its gratitude to Mr. Li for his contribution to the Company during his tenure of office.

#### **APPOINTMENT OF EXECUTIVE DIRECTOR AND CHIEF EXECUTIVE OFFICER**

The Board also announces that Mr. Yan Yifan (“**Mr. Yan**”) has been appointed as an executive Director and the chief executive officer of the Company with effect from 8 April 2022.

Mr. Yan, aged 31, graduated from Henan University of Economics and Law. He has served as the general manager of Mailyard Health Group (Hubei) Company Limited since April 2021 and served as the general manager of Zhong Ji 1 International Medical Group (Hong Kong), the shares of which are beneficially owned by Mr. Yan Li, the chairman of the Board and an executive director, from July 2013 to March 2021.

Mr. Yan is also the nephew of Mr. Yan Li, the chairman of the Board and an executive Director.

As at the date of this announcement, Mr. Yan has confirmed that save as disclosed above, he (i) does not have any relationship with any Director, senior management, or substantial or controlling shareholder (as defined in the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) (the “**Listing Rules**”)) of the Company; (ii) does not have, and is not deemed to have, any interest in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong); (iii) does not hold any other directorship in the last three years in public companies, the securities of which are listed on any securities market in Hong Kong or overseas; and (iv) does not hold any other positions in the Group.

Pursuant to the appointment letter entered into by the Company and Mr. Yan, Mr. Yan is not appointed for any specific or proposed term of service, but is subject to retirement by rotation and re-election (if applicable) at an annual general meeting at least once every three years in accordance with the bye-laws of the Company and the Corporate Governance Code set out in Appendix 14 to the Listing Rules. He is entitled to receive a director’s fee of HK\$100,000 per month, which is determined by the Board and is subject to annual review with reference to the prevailing market condition, his duties and responsibilities in and the time he spent on the affairs of the Company.

Save as disclosed above, there is no other information in relation to the appointment of Mr. Yan as a Director to be disclosed pursuant to any of the requirements of Rule 13.51(2) of the Listing Rules, and there is no other matter that needs to be brought to the attention of the shareholders of the Company. The Company believes that Mr. Yan will bring valuable contributions to the Group. The Board would like to extend its welcome to Mr. Yan for joining the Company.

#### **RESIGNATION OF INDEPENDENT NON-EXECUTIVE DIRECTOR**

The Board hereby announces that Ms. Wang Weixia (“**Ms. Wang**”) and Mr. Chai Nan (“**Mr. Chai**”) have resigned as independent non-executive Directors due to personal and other business affairs with effect from 7 April 2022.

Both of Ms. Wang and Mr. Chai have confirmed to the Board that they have no disagreement with the Board and there is no matter relating to their resignation that needs to be brought to the attention of the shareholders of the Company. The Board would like to take this opportunity to express its gratitude to Ms. Wang and Mr. Chai for their contribution to the Company during their tenure of office.

#### **APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR**

The Board also announces that Mr. Wang Ning (“**Mr. Wang**”) and Professor Huang Cibo (“**Prof. Huang**”) have been appointed as independent non-executive Directors with effect from 8 April 2022.

The biographical details of Mr. Wang are set out as follows:

Mr. Wang, aged 43, obtained an EMBA from Fudan University, Shanghai, and graduated from Anhui Normal University, majoring in hotel management. He currently serves as the chairman of Huasheng Investment Group, the chairman of the board and a non-executive director of National Investments Fund Limited, a company listed on Main Board of the Stock Exchange (stock code: 1227). He served as an independent non-executive director of RMH Holdings Limited, a company listed on GEM of the Stock Exchange (stock code: 8437), the vice president of Youth Committee of Shenzhen International Chamber of Commerce (深圳國際商會青年委員會副主席) and the president of Shenzhen Youth Entrepreneur Promotion Association\* (深圳市青年創業促進會會長). Mr. Wang is experienced in real estate development, corporate management, venture capital, and the management of real estate and investment companies listed on the Stock Exchange.

As at the date of this announcement, Mr. Wang has confirmed that save as disclosed above, he (i) does not have any relationship with any Director, senior management, or substantial or controlling shareholder (as defined in the Listing Rules) of the Company; (ii) does not have, and is not deemed to have, any interest in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong); (iii) does not hold any other directorship in the last three years in public companies, the securities of which are listed on any securities market in Hong Kong or overseas; and (iv) does not hold any other positions in the Group.

Mr. Wang has entered into an appointment letter with the Company with an initial term of two years. Mr. Wang is subject to retirement by rotation and re-election, if applicable, at the annual general meeting at least once every three years in accordance with the bye-laws of the Company and the Corporate Governance Code set out in Appendix 14 to the Listing Rules. He is entitled to receive a director's fee of HK\$20,000 per month, which is determined by the Board, subject to annual review with reference to the prevailing market conditions, his duties and responsibilities and time spent on the affairs of the Company.

Save as disclosed above, there is no other information in relation to the appointment of Mr. Wang to be disclosed pursuant to any of the requirements of Rule 13.51(2) of the Listing Rules, and there is no other matter that needs to be brought to the attention of the shareholders of the Company.

The biographical details of Prof. Huang are set out as follows:

Prof. Huang, aged 59, graduated from the Department of Medicine of Xiangya School of Medicine (湘雅醫科大學), is among the first batch of renowned doctors in the PRC. He currently serves as the director of the Internal Medicine Branch of the Chinese Medical Association, the vice president of the Rheumatology and Immunology Branch and the director of the Immunosorbent Branch of the Chinese Medical Doctor Association, the director of the Rheumatology Branch of the Cross-Straits Medical and Health Exchange

Association, and the special consultation expert of the Central Health Care Committee. He has worked in 301 Hospital, Southern Hospital, People's Hospital of the Guangdong Province and Beijing Hospital for nearly 40 years, mainly engaged in clinical diagnosis and treatment of internal medicine and rheumatic immune diseases, scientific research and teaching, and health care work for local senior cadres of the military.

As at the date of this announcement, Prof. Huang has confirmed that save as disclosed above, he (i) does not have any relationship with any Director, senior management, or substantial or controlling shareholder (as defined in the Listing Rules) of the Company; (ii) does not have, and is not deemed to have, any interest in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong); (iii) does not hold any other directorship in the last three years in public companies, the securities of which are listed on any securities market in Hong Kong or overseas; and (iv) does not hold any other positions in the Group.

Prof. Huang has entered into an appointment letter with the Company with an initial term of two years. Prof. Huang is subject to retirement by rotation and re-election, if applicable, at the annual general meeting at least once every three years in accordance with the bye-laws of the Company and the Corporate Governance Code set out in Appendix 14 to the Listing Rules. He is entitled to receive a director's fee of HK\$20,000 per month, which is determined by the Board, subject to annual review with reference to the prevailing market conditions, his duties and responsibilities and time spent on the affairs of the Company.

Save as disclosed above, there is no other information in relation to the appointment of Prof. Huang to be disclosed pursuant to any of the requirements of Rule 13.51(2) of the Listing Rules, and there is no other matter that needs to be brought to the attention of the shareholders of the Company.

The Board would like to extend its welcome to Mr. Wang and Prof. Huang for his new position in the Company.

## **CHANGE OF MEMBERS OF BOARD COMMITTEES**

The Board further announces:

- (i) Ms. Wang Weixia ceased to be the chairman of the remuneration committee and a member of each of the audit committee, the nomination committee, the risk management committee and the share award committee of the Board with effect from 7 April 2022;
- (ii) Mr. Chai Nan ceased to be a member of each of the audit committee, the remuneration committee, the nomination committee, the risk management committee and the share award committee of the Board with effect from 7 April 2022;

- (iii) Mr. Wang Ning has been appointed as the chairman of the remuneration committee and a member of each of the audit committee, the nomination committee, the risk management committee and the share award committee of the Board with effect from 8 April 2022;
- (iv) Professor Huang Cibo has been appointed as a member of each of the audit committee, the remuneration committee, the nomination committee, the risk management committee and the share award committee of the Board with effect from 8 April 2022; and
- (v) Mr. Yan Li, the chairman of the Board and an executive Director, has been appointed to replaced Mr. Lee See Barry as the chairman of the risk management committee of the Board with effect from 8 April 2022.

By order of the Board  
**Zhong Ji Longevity Science Group Limited**  
**Yan Li**  
*Chairman*

Hong Kong, 8 April 2022

*As at the date of this announcement, the Directors are:*

*Executive Directors*

Mr. Yan Li (*Chairman*)  
Mr. Yan Yifan (*Chief Executive Officer*)  
Mr. Li Xiaoshuang  
Ms. Cao Xie Qiong

*Independent non-executive Directors*

Mr. Tam Ho Leung Simon  
Mr. Lee See Barry  
Mr. Wang Ning  
Prof. Huang Cibo

*Non-executive Directors*

Dr. He Yiwu  
Ms. Choi Ngai Wah

*In the case of any inconsistency, the English text of this announcement shall prevail over the Chinese text.*

\* *For identification purpose only*